Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

NCT00663026 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: bapineuzumab
DRUG: bapineuzumab
DRUG: placebo

Sponsor

Pfizer